التداخل بين دينوسوماب وباريكالسيتول

Monitor calcium levels during therapy, especially in the first weeks of initiating therapy, and adequately supplement all patients with calcium and vitamin D.

Monitor calcium levels, throughout Bilprevda therapy, especially in the first weeks of initiating therapy, and administer calcium, magnesium, and vitamin D as necessary.

Monitor calcium levels and calcium and vitamin D intake [see Adverse Reactions ( 6.1 ), Use in Specific Populations ( 8.6 ), and Clinical Pharmacology ( 12.3 )] .

After treatment is discontinued, monitor patients for signs and symptoms of hypercalcemia, assess serum calcium periodically, reevaluate the patient's calcium and vitamin D supplementation requirements and manage patients as clinically appropriate [see Adverse Reactions ( 6 ) and Use in Specific Populations ( 8.4 )] .